Alpha Paradigm Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Alpha Paradigm Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$474K	Buy	10,241 +3,496	+52%	+$138K	0.2%	176
2022 Q3	$279K	Buy	+6,745	New	+$347K	0.12%	250
2022 Q2	–	Sell	-6,806	Closed	-$494K	–	612
2022 Q1	$494K	Buy	6,806 +5,464	+407%	+$380K	0.19%	176
2021 Q4	$113K	Buy	+1,342	New	+$109K	0.05%	413

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Alpha Paradigm Partners's RARE Position: Q4 2022 in Review

Alpha Paradigm Partners increased its Ultragenyx Pharmaceutical (RARE) stake by 52% in Q4 2022, buying an estimated $138K and bringing the position to 10,241 shares worth $474K. The position accounts for 0.2% of the portfolio, ranked #176.

Alpha Paradigm Partners first reported a position in RARE in Q4 2021 and has held it in 4 quarters since. The position peaked at $494K in Q1 2022. 227 funds tracked by Wall St. Rank hold RARE as of Q4 2022.

Alpha Paradigm Partners held 10,241 shares of Ultragenyx Pharmaceutical worth $474K as of Q4 2022.
Alpha Paradigm Partners bought 3,496 Ultragenyx Pharmaceutical shares in Q4 2022, an estimated $138K.
Ultragenyx Pharmaceutical made up 0.2% of Alpha Paradigm Partners's portfolio in Q4 2022, its #176 holding.
Alpha Paradigm Partners first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and has held it in 4 quarters since.
Alpha Paradigm Partners's Ultragenyx Pharmaceutical position peaked at $494K in Q1 2022.
227 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.